US20030170177A1 - Lipid-binding proteins and their therapeutic and diagnostic use - Google Patents
Lipid-binding proteins and their therapeutic and diagnostic use Download PDFInfo
- Publication number
- US20030170177A1 US20030170177A1 US10/308,960 US30896002A US2003170177A1 US 20030170177 A1 US20030170177 A1 US 20030170177A1 US 30896002 A US30896002 A US 30896002A US 2003170177 A1 US2003170177 A1 US 2003170177A1
- Authority
- US
- United States
- Prior art keywords
- lipid
- microparticle
- hsa
- albumin
- microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000019758 lipid binding proteins Human genes 0.000 title claims abstract description 12
- 230000001225 therapeutic effect Effects 0.000 title claims description 6
- 108091016323 lipid binding proteins Proteins 0.000 title description 4
- 239000011859 microparticle Substances 0.000 claims abstract description 37
- 108010088751 Albumins Proteins 0.000 claims abstract description 16
- 150000002632 lipids Chemical class 0.000 claims abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 101710129138 ATP synthase subunit 9, mitochondrial Proteins 0.000 claims abstract description 8
- 101710168506 ATP synthase subunit C, plastid Proteins 0.000 claims abstract description 8
- 101710114069 ATP synthase subunit c Proteins 0.000 claims abstract description 8
- 101710197943 ATP synthase subunit c, chloroplastic Proteins 0.000 claims abstract description 8
- 101710187091 ATP synthase subunit c, sodium ion specific Proteins 0.000 claims abstract description 8
- 238000001415 gene therapy Methods 0.000 claims abstract description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 35
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 35
- 102000009027 Albumins Human genes 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 125000002091 cationic group Chemical group 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 4
- 239000002961 echo contrast media Substances 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims 2
- 238000012285 ultrasound imaging Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000003384 imaging method Methods 0.000 abstract description 2
- 102100027211 Albumin Human genes 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 description 27
- 150000004665 fatty acids Chemical class 0.000 description 19
- 235000014113 dietary fatty acids Nutrition 0.000 description 18
- 239000000194 fatty acid Substances 0.000 description 18
- 229930195729 fatty acid Natural products 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000001694 spray drying Methods 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 150000004668 long chain fatty acids Chemical class 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- -1 DC-Chol Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000252203 Clupea harengus Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010028921 Lipopeptides Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical group NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 1
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- JLSKPBDKNIXMBS-VIFPVBQESA-N L-tryptophanamide Chemical compound C1=CC=C2C(C[C@H](N)C(N)=O)=CNC2=C1 JLSKPBDKNIXMBS-VIFPVBQESA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/225—Microparticles, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
Definitions
- This invention relates to lipid-binding proteins such as defatted albumin, especially as a spray-dried product, and to their therapeutic and diagnostic use. More particularly, the invention relates to microparticles that can be used as carriers in therapy, e.g. gene therapy, and to the combination of carrier and therapeutic agent.
- Human serum albumin is a protein whose production in the form of microparticles having a size suitable for use in therapy by parenteral administration or by inhalation, alone or as a carrier for an active agent, e.g. in a metered dose inhaler, is disclosed in WO-A-9609814 and in WO-A-9618388.
- the HSA may be used as such or as a carrier for a desired active agent, since appropriate spray-drying conditions do not denature the protein or essentially reduce the existence of groups available for binding.
- albumin microparticles may be produced in soluble form and then stabilised, for use as diagnostic agents.
- WO-A-9618388 discloses that such products can be conjugated to therapeutic agents.
- WO-9609814 discloses that the soluble microparticles are not denaturated, and therefore retain therapeutic utility.
- Fatty acids give added stability to the HSA molecule, and the conformation and subsequent ability to bind ligands are affected by the amount and type of fatty acid bound. Fatty acids also protect against thermal denaturation and the ability of HSA to recover from thermal shock. Long chain fatty acids appear to be better than shorter chain fatty acids. See Brown and Shockley (1982), in “Lipid Protein Interactions”, Ed. P. C. Jost and O. H. Griffith, vol 1, pp 25-68, John Wiley, NY; Kragh-Hanson (1990), Danish Medical Bulletin 37:57-84; and Carter and Ho (1994), Advances In Protein Chemistry 45:153-203.
- lipid-bound proteins such as albumin may associate only weakly with DNA, but that lipid-binding proteins such as defatted albumin, provided as microparticles, have surprisingly enhanced association with DNA.
- short-chain fatty acids e.g. octanoate
- HSA defatting of HSA may therefore make available some or all of the 6-7 high affinity long-chain fatty acid sites and further high affinity short-chain sites.
- defatted HSA lipid-binding proteins
- DNA being anionic
- defatted albumins can be loaded with a wide range of fatty acids, e.g. DC-Chol, or other ligands which would otherwise be inhibited by the presence of the naturally-bound fatty acids. The removal of fatty acids liberates not only these sites but also makes available binding sites for aspirin or other drugs.
- the removal of a mixed population of fatty acids (and probably other ligands) allows the reloading of specific fatty acids, drugs or intermediate ligands to assist in the stability, conformational structure and/or binding capabilities of microparticles of defatted albumin.
- the reloading of, for example, aminocaprylic acid may be achieved prior to or after spray-drying of defatted albumin, to give a cationic capsule for DNA binding and parenteral delivery.
- the microparticles may also be loaded, at the time of administration, with a drug-bound fatty acid (ligand) complex, potentially improving usage, storage, stability and applications.
- microparticles of the invention having a modified, predetermined fatty acid profile may be used as enhanced ultrasound contrast agents.
- Microparticles according to the invention are obtainable by spray-drying. Suitable conditions are described in WO-A-9218164, WO-A-9609814 and WO-A-9618388. These publications also describe relevant parameters of the microparticles, as regards formulation, size, size distribution etc. These parameters are also preferred for microparticles of this invention. Size and size distribution may be less critical than has been described in the given particles for, say, administration to the alveoli. Microparticles of this invention may be nanoparticles or larger, e.g. up to 50 ⁇ m in diameter.
- the microparticles may comprise additional components adapted for a particular use.
- lipid may enhance cell membrane interaction and thus enhance uptake.
- the lipid itself or any additional component may be introduced by co-spray-drying or by modification of the formed microparticles, before or after stabilisation.
- An additional component may be introduced by co-spray-drying or by modification of the formed microparticles, before or after stabilisation.
- lipid-bound protein such as albumin is defatted. This may be achieved, i.e. fatty acids may be removed, by using acidified activated charcoal, as described by Chen, J. Biol. Chem. 242:173-181 (1967). The charcoal should be washed. Alternatively, solvent extraction may be used.
- An albumin is the preferred lipid-binding protein for use in this invention, e.g. in soluble or microparticulate form.
- the albumin may be naturally-occurring or recombinant. For the purpose of illustration only, the invention will be described below with reference to HSA.
- Clinical grade HSA is normally formulated with octanoate (in the presence or absence of tryptophanamide). After removal of this, and defatting, a cationic version of this lipid (e.g. aminocaprylic or aminocaproic acid) can be bound to HSA or HSA microcapsules. Other cationic lipids can also be loaded, pre- or post-spray-drying, producing a vehicle for parenteral delivery of non-viral gene vectors.
- octanoate in the presence or absence of tryptophanamide.
- Other cationic lipids can also be loaded, pre- or post-spray-drying, producing a vehicle for parenteral delivery of non-viral gene vectors.
- Cationic and/or anionic lipids or ligands that bind to free fatty acid-binding sites on HSA can be used to modify the charge and hydrophilicity or hydrophobicity of the microcapsule. This may be advantageous for the targeting of microcapsules for delivery of cytotoxic and other drugs to specific organs such as lung, liver, spleen etc. For example, by appropriate charge modification, a product of this invention may be adapted to bypass the liver and be transported to the lung.
- the reloading of, for example, long-chain fatty acids may lead to an altered but more stable configuration of the protein.
- the molecules may be modified accordingly, to produce microcapsules with modified shell structure relative to the stabilised/cross-linked products described in WO-A-9218164 (available from Andaris Limited under the trade name Quantison), for improved drug delivery and also for better echogenicity for imaging.
- a therapeutic agent may be complexed with or loaded directly onto defatted HSA microparticles.
- a fatty acid-agent complex may be formed, e.g. by covalent binding, and used to reload the defatted microparticles.
- the lipid that is loaded may itself be a therapeutic agent.
- the invention is of utility as a vaccine delivery system, e.g. using a lipopeptide.
- a polycationic or polyanionic tail on the end of a peptide allows the loading of microcapsules with proteinaceous material, and thus provides a means of delivering antigenic peptides.
- a suitable lipopeptide is described by Allsopp et al, Eur. J. Immunol. (1996) 26:1951-9, where a lipid-tailed peptide induced high levels of cytotoxic T lymphocytes.
- the amount of therapeutic agent that is used according to the invention, and its formulation (e.g. with a suitable diluent or carrier) and administration, may be conventional. These factors can readily be determined by one of ordinary skill in the art, depending on the nature and degree of the desired effect.
- Microcapsules were prepared under the same conditions from HSA (Example A), defatted HSA (Example 1) and aminocaprylic acid or lysine with defatted HSA (Examples 2 and 3, respectively). The DNA-binding properties of each product were investigated.
- HSA microcapsules bound 4.5% w/w DNA. This was much greater than expected. Aminocaprylic acid and lysine both enhanced the DNA association, giving loadings of 7.8% and 5.9% w/w respectively. Control HSA microcapsules only weakly associated with DNA, as expected.
- the concentration of aminocaprylic acid loaded onto defatted HSA in Example 2 was determined by amino-acid analysis using pre-column derivatisation with o-phthaldialdehyde reagent (OPA). A series of standards was prepared by derivatising aminocaprylic acid with OPA.
- OPA o-phthaldialdehyde reagent
- the charcoal was removed from the solution by centrifugation at 10,000 rpm for 20 minutes.
- the supernatants were sterile-filtered (0.2 ⁇ m).
- the defatted HSA solution was then diafiltered with 5 volumes purified water before being concentrated to 250 mg/ml.
- the pH was adjusted to 7.0 before the concentration process.
- the concentrated defatted HSA was sterile-filtered and stored at 4° C.
- a feedstock for spray-drying was prepared, using the defatted HSA in a 100 mg/ml concentration, ethanol at 25% of the feedstock volume, and purified water.
- the Niro Mobile Minor was employed under the following conditions: Inlet Temperature 220° C. Outlet Temperature 99° C. Atomisation Type 2 fluid nozzle Atomisation Pressure 7.5 barg
- the resultant microcapsules were stabilised (176° C., 55 minutes) and deagglomerated, under conditions as described in WO-A-9218164.
- microcapsules from Examples 4, 5 and 6 were assessed for their suitability as enhanced ultrasound contrast agents.
- the assessment of their acoustic scattering properties was carried out using two techniques with a commercially-available ultrasound scanner equipped with a 3.5 MHz transducer (Model SONOS 1000, Hewlett Packard).
- Example 4 Example 5
- Example 6 80 2 44 2 85 3 38 3 90 7 51 3 92 9 63 4 94 11 69 5 96 19 85 7 98 26 86 9 100 38 110 14 102 43 113 23 104 67 130 35 106 92 147 64 108 124 149 95 110 146 150 132 115 150 151 152 128 147 150 148
- DNA was bound to each of the microcapsule batches of Examples 4-6, and also to a control.
- Four aliquots of 15 mg of each of the four batches were weighed out, each aliquot containing 5 mg microcapsules.
- 0.5 ml DNA solution (2 mg/ml, Herring Testes) was added, and the resultant solutions were placed on a shaker table for 16 hours at room temperature.
- the fourth aliquot for each batch was retained as a control.
- An aliquot of the DNA solution was left for 16 hours as a control.
- Example 5 The microcapsules of Example 5, i.e. comprising the cationic lipid DC-Chol, or 3 ⁇ -[N-(N′,N′-dimethylamino-ethane)carbamoyl]cholesterol, were again bound to DNA.
- the DNA was the commercially-available luciferase reporter plasmid pGL3-control (Promega). This plasmid contains the SV40 promoter and enhancer driving the expression of the firefly luciferase gene. Upon transfection of this plasmid into mammalian cells, transcription of the luciferase gene at high levels leads to a high level of luciferase enzyme expressed within the cells.
- the activity of the luciferase enzyme can be readily assayed in cell lysates, using commercially-available reagents. Since mammalian cells possess no endogenous luciferase gene, enzyme activity in transfected cells can be correlated with the efficiency of transfection of the pGL3 plasmid.
- microcapsules were incubated with 20 ⁇ g pGL3 plasmid in PBS buffer for 2 hours.
- the DNA-loaded microcapsules were washed and resuspended in Optimem (cell culture medium) and then incubated with A549 (human lung carcinoma) and HeLa (human cervical epithelial carcinoma) cells at 5 ⁇ 10 5 per well for between 2 and 28 hours at 37° C.
- Optimem cell culture medium
- A549 human lung carcinoma
- HeLa human cervical epithelial carcinoma
Abstract
The present invention pertains to microparticles of a lipid-binding protein such as defatted albumin or microparticles of such a protein having a non-natural lipid profile are useful in therapy, e.g., as a vehicle for gene therapy, and in imaging.
Description
- This invention relates to lipid-binding proteins such as defatted albumin, especially as a spray-dried product, and to their therapeutic and diagnostic use. More particularly, the invention relates to microparticles that can be used as carriers in therapy, e.g. gene therapy, and to the combination of carrier and therapeutic agent.
- Human serum albumin (HSA) is a protein whose production in the form of microparticles having a size suitable for use in therapy by parenteral administration or by inhalation, alone or as a carrier for an active agent, e.g. in a metered dose inhaler, is disclosed in WO-A-9609814 and in WO-A-9618388. The HSA may be used as such or as a carrier for a desired active agent, since appropriate spray-drying conditions do not denature the protein or essentially reduce the existence of groups available for binding.
- As described in WO-A-9218164, albumin microparticles may be produced in soluble form and then stabilised, for use as diagnostic agents. WO-A-9618388 discloses that such products can be conjugated to therapeutic agents. WO-9609814 discloses that the soluble microparticles are not denaturated, and therefore retain therapeutic utility.
- HSA is known to bind a wide range of ligands including drugs, dyes, toxic compounds (e.g. bilirubin) and hydrophobic molecules such as fatty acids. Fatty acid transport is possibly one of the most important functions of HSA. A loading of up to two molecules of lipid is considered normal with a high turnover rate. HSA has the ability to bind fatty acids with high affinity, and this appears to increase with the increasing length of the fatty acid chain. Very high affinities (Ka=107−109) have been reported for long chain fatty acids. HSA is capable of binding up to 6-7 molecules of fatty acid/molecules of protein with moderate to high affinities. Low affinity binding of fatty acids, in numbers as high as 60 molecules of fatty acids/HSA molecule, has been reported.
- Fatty acids give added stability to the HSA molecule, and the conformation and subsequent ability to bind ligands are affected by the amount and type of fatty acid bound. Fatty acids also protect against thermal denaturation and the ability of HSA to recover from thermal shock. Long chain fatty acids appear to be better than shorter chain fatty acids. See Brown and Shockley (1982), in “Lipid Protein Interactions”, Ed. P. C. Jost and O. H. Griffith, vol 1, pp 25-68, John Wiley, NY; Kragh-Hanson (1990), Danish Medical Bulletin 37:57-84; and Carter and Ho (1994), Advances In Protein Chemistry 45:153-203.
- It has now been discovered that lipid-bound proteins such as albumin may associate only weakly with DNA, but that lipid-binding proteins such as defatted albumin, provided as microparticles, have surprisingly enhanced association with DNA. Without wishing to be bound by theory, we note that short-chain fatty acids (e.g. octanoate) are not removed by long-chain fatty acids, suggesting that higher affinity short-chain sites occupy the lower affinity long-chain sites on, say, HSA. Defatting of HSA may therefore make available some or all of the 6-7 high affinity long-chain fatty acid sites and further high affinity short-chain sites.
- The ability of lipid-binding proteins such as defatted HSA to associate with DNA may be further enhanced by the addition of a cationic molecule (DNA being anionic). It is a feature of this invention that defatted albumins can be loaded with a wide range of fatty acids, e.g. DC-Chol, or other ligands which would otherwise be inhibited by the presence of the naturally-bound fatty acids. The removal of fatty acids liberates not only these sites but also makes available binding sites for aspirin or other drugs. The removal of a mixed population of fatty acids (and probably other ligands) allows the reloading of specific fatty acids, drugs or intermediate ligands to assist in the stability, conformational structure and/or binding capabilities of microparticles of defatted albumin. The reloading of, for example, aminocaprylic acid may be achieved prior to or after spray-drying of defatted albumin, to give a cationic capsule for DNA binding and parenteral delivery. The microparticles may also be loaded, at the time of administration, with a drug-bound fatty acid (ligand) complex, potentially improving usage, storage, stability and applications.
- Further, microparticles of the invention having a modified, predetermined fatty acid profile may be used as enhanced ultrasound contrast agents.
- Microparticles according to the invention are obtainable by spray-drying. Suitable conditions are described in WO-A-9218164, WO-A-9609814 and WO-A-9618388. These publications also describe relevant parameters of the microparticles, as regards formulation, size, size distribution etc. These parameters are also preferred for microparticles of this invention. Size and size distribution may be less critical than has been described in the given particles for, say, administration to the alveoli. Microparticles of this invention may be nanoparticles or larger, e.g. up to 50 μm in diameter.
- The microparticles may comprise additional components adapted for a particular use. For example, lipid may enhance cell membrane interaction and thus enhance uptake. The lipid itself or any additional component may be introduced by co-spray-drying or by modification of the formed microparticles, before or after stabilisation.
- An additional component may be introduced by co-spray-drying or by modification of the formed microparticles, before or after stabilisation.
- For use in this invention, a lipid-bound protein such as albumin is defatted. This may be achieved, i.e. fatty acids may be removed, by using acidified activated charcoal, as described by Chen, J. Biol. Chem. 242:173-181 (1967). The charcoal should be washed. Alternatively, solvent extraction may be used.
- An albumin is the preferred lipid-binding protein for use in this invention, e.g. in soluble or microparticulate form. The albumin may be naturally-occurring or recombinant. For the purpose of illustration only, the invention will be described below with reference to HSA.
- Clinical grade HSA is normally formulated with octanoate (in the presence or absence of tryptophanamide). After removal of this, and defatting, a cationic version of this lipid (e.g. aminocaprylic or aminocaproic acid) can be bound to HSA or HSA microcapsules. Other cationic lipids can also be loaded, pre- or post-spray-drying, producing a vehicle for parenteral delivery of non-viral gene vectors. The utility of albumin microparticles, as a vehicle for gene therapy, and suitable constituents and conditions, are disclosed in PCT/GB97/00953, the contents of which are incorporated herein by reference.
- Cationic and/or anionic lipids or ligands that bind to free fatty acid-binding sites on HSA can be used to modify the charge and hydrophilicity or hydrophobicity of the microcapsule. This may be advantageous for the targeting of microcapsules for delivery of cytotoxic and other drugs to specific organs such as lung, liver, spleen etc. For example, by appropriate charge modification, a product of this invention may be adapted to bypass the liver and be transported to the lung.
- The reloading of, for example, long-chain fatty acids may lead to an altered but more stable configuration of the protein. The molecules may be modified accordingly, to produce microcapsules with modified shell structure relative to the stabilised/cross-linked products described in WO-A-9218164 (available from Andaris Limited under the trade name Quantison), for improved drug delivery and also for better echogenicity for imaging.
- In a therapeutic product of the invention, a therapeutic agent may be complexed with or loaded directly onto defatted HSA microparticles. Alternatively, a fatty acid-agent complex may be formed, e.g. by covalent binding, and used to reload the defatted microparticles.
- The lipid that is loaded may itself be a therapeutic agent. For example, the invention is of utility as a vaccine delivery system, e.g. using a lipopeptide. The inclusion of a polycationic or polyanionic tail on the end of a peptide allows the loading of microcapsules with proteinaceous material, and thus provides a means of delivering antigenic peptides. A suitable lipopeptide is described by Allsopp et al, Eur. J. Immunol. (1996) 26:1951-9, where a lipid-tailed peptide induced high levels of cytotoxic T lymphocytes.
- The amount of therapeutic agent that is used according to the invention, and its formulation (e.g. with a suitable diluent or carrier) and administration, may be conventional. These factors can readily be determined by one of ordinary skill in the art, depending on the nature and degree of the desired effect.
- Microcapsules were prepared under the same conditions from HSA (Example A), defatted HSA (Example 1) and aminocaprylic acid or lysine with defatted HSA (Examples 2 and 3, respectively). The DNA-binding properties of each product were investigated.
- Triplicate aliquots of each product (5 mg microcapsules) were incubated with DNA (2 mg/ml aqueous, Sigma herring) at room temperature for 16 hours. The uptake of DNA by the microcapsules was determined spectrophotometrically. Results are given in Table 1.
TABLE 1 Mean Particle DNA Association Example Diameter (μm) (% w/w) 1 4.34 4.5 2 3.15 7.8 3 3.96 5.9 A 3.04 0.8 - Surprisingly, defatted HSA microcapsules bound 4.5% w/w DNA. This was much greater than expected. Aminocaprylic acid and lysine both enhanced the DNA association, giving loadings of 7.8% and 5.9% w/w respectively. Control HSA microcapsules only weakly associated with DNA, as expected.
- The concentration of aminocaprylic acid loaded onto defatted HSA in Example 2 was determined by amino-acid analysis using pre-column derivatisation with o-phthaldialdehyde reagent (OPA). A series of standards was prepared by derivatising aminocaprylic acid with OPA.
- Calculations have determined that the loading of aminocaprylic acid onto defatted HSA was 0.87 μg per 1 mg HSA microcapsules, i.e., 0.087% w/w. This is equivalent to 5.4 nmoles aminocaprylic acid per mg HSA (or per 15 nmoles protein).
- 261 g activated charcoal (Sigma, 73H0369) was resuspended in 2500 ml purified water. The resultant suspension was sieved (0.45 μm) and washed with 15 l purified water. The washed charcoal was spread evenly over a metal tray and dried in the laboratory oven for 8 hours at 65° C.
- 8000 ml of HSA (Armour US, N28510, 5%) was divided into 1000 ml glass bottles. 31.25 g of the washed charcoal was added to each bottle. The pH of each suspension was lowered to 3.0 using concentrated hydrochloric acid. The bottles were then placed in an ice bath and were vigorously shaken every 10 minutes. After 90 minutes, the bottles were removed from the ice bath.
- The charcoal was removed from the solution by centrifugation at 10,000 rpm for 20 minutes. The supernatants were sterile-filtered (0.2 μm). The defatted HSA solution was then diafiltered with 5 volumes purified water before being concentrated to 250 mg/ml. The pH was adjusted to 7.0 before the concentration process. The concentrated defatted HSA was sterile-filtered and stored at 4° C.
- A feedstock for spray-drying was prepared, using the defatted HSA in a 100 mg/ml concentration, ethanol at 25% of the feedstock volume, and purified water. The Niro Mobile Minor was employed under the following conditions:
Inlet Temperature 220° C. Outlet Temperature 99° C. Atomisation Type 2 fluid nozzle Atomisation Pressure 7.5 barg - The resultant microcapsules were stabilised (176° C., 55 minutes) and deagglomerated, under conditions as described in WO-A-9218164.
- Two fatty acids of different chain lengths were selected: DC-Chol (example 5) and amino-n-caproic acid (Example 6). A 2% loading of each lipid onto the microcapsule was attempted.
- 300 mg deagglomerated defatted HSA microcapsules (containing 100 mg protein and 200 mg mannitol excipient) were washed and centrifuged (3000 rpm, 3 minutes). The pellet was resuspended in 5 ml of the respective lipid solution (containing 2 mg lipid). The DC-Chol required dissolution in chloroform before reconstitution in 5 ml purified water.
- The solutions were left for 30 minutes on the roller mixer, after which the solutions were centrifuged (3000 rpm, 10 minutes). The supernatants were discarded whilst the pellets were resuspended in 5 ml mannitol solution (50.8 mg/ml) before freeze-drying.
- Acoustic Scattering
- The microcapsules from Examples 4, 5 and 6 were assessed for their suitability as enhanced ultrasound contrast agents. The assessment of their acoustic scattering properties was carried out using two techniques with a commercially-available ultrasound scanner equipped with a 3.5 MHz transducer (Model SONOS 1000, Hewlett Packard).
- For the first assessment, a background measurement was taken of a stirred 400 ml polypropylene test beaker containing 350 ml of gas-equilibrated water at ambient temperature with the transducer face immersed to a depth of 1.5 cm.
- The following instrument settings were used:
Transmit = 60 dB Total Gain Controls = 128 Compression = 128 Depth = 8 cm Persistence = 0 - 5 mg of the microcapsules evenly dispersed in 250 μl of water were then carefully added to the stirred beaker and a further measurement made. The measurements were assessed by using image analysis to give a numerical value to the brightness seen on the monitor, known as visual display units (VDUs). When the background is subtracted, the relative echogenicity of the microcapsules can be found. All measurements were repeated in triplicate and are shown in Table 2. It can be observed that DC-Chol-loaded microcapsules exhibit enhanced scattering properties.
TABLE 2 Echogenicity (VDUs) Sample Assay 1 Assay 2 Assay 3 Example 4 39 39 41 Example 5 63 66 61 Example 6 32 34 35 - The second assessment of echogenicity used a similar arrangement to the first, with a larger stirred polypropylene test beaker containing 1000 ml of gas-equilibrated water at 37° C. Again, a background measurement was taken with the following instrument settings, to ensure that no significant background reading was present.
Transmit = 128 dB Total Gain Controls = 128 Compression = 1 Depth = 8 cm Persistence = 0 - 4 mg of the microcapsules evenly dispersed in 200 μl of water were then carefully added to the stirred beaker, and further measurements made as the transmit power was incremently increased from 80 to 128 dB. Again, the measurements were assessed by using image analysis, to give a numerical value to the brightness. The results are shown in Table 3. It can be seen that again the DC-Chol-loaded microcapsules exhibit enhanced scattering properties at lower transmit power levels.
TABLE 3 Transmit Echogenicity (VDUs) Power (dB) Example 4 Example 5 Example 6 80 2 44 2 85 3 38 3 90 7 51 3 92 9 63 4 94 11 69 5 96 19 85 7 98 26 86 9 100 38 110 14 102 43 113 23 104 67 130 35 106 92 147 64 108 124 149 95 110 146 150 132 115 150 151 152 128 147 150 148 - DNA was bound to each of the microcapsule batches of Examples 4-6, and also to a control. Four aliquots of 15 mg of each of the four batches were weighed out, each aliquot containing 5 mg microcapsules. To 3 of the 4 aliquots, 0.5 ml DNA solution (2 mg/ml, Herring Testes) was added, and the resultant solutions were placed on a shaker table for 16 hours at room temperature. The fourth aliquot for each batch was retained as a control. An aliquot of the DNA solution was left for 16 hours as a control.
- After 16 hours, the samples were centrifuged (15,000 rpm, 2 minutes), and the supernatants were diluted 1:40 and filtered. The samples were then scanned at 400-190 nm using the UV/VIS spectrophotometer. The results are given in Table 4.
TABLE 4 Microcapsule Count DNA Association Sample per mg (μg/mg Capsules) Control 2.5 × 106 — Example 7 1.56 × 107 32 (3.2% w/w) Example 8 1.56 × 107 77.0 (7.7% w/w) Example 9 1.56 × 107 100.6 (10.06% w/w) - The microcapsules of Example 5, i.e. comprising the cationic lipid DC-Chol, or 3β-[N-(N′,N′-dimethylamino-ethane)carbamoyl]cholesterol, were again bound to DNA. The DNA was the commercially-available luciferase reporter plasmid pGL3-control (Promega). This plasmid contains the SV40 promoter and enhancer driving the expression of the firefly luciferase gene. Upon transfection of this plasmid into mammalian cells, transcription of the luciferase gene at high levels leads to a high level of luciferase enzyme expressed within the cells. The activity of the luciferase enzyme can be readily assayed in cell lysates, using commercially-available reagents. Since mammalian cells possess no endogenous luciferase gene, enzyme activity in transfected cells can be correlated with the efficiency of transfection of the pGL3 plasmid.
- The procedures for binding DNA onto the cationic lipid containing microcapsules and the subsequent gene transfection experiments were as follows:
- 20 mg microcapsules were incubated with 20 μg pGL3 plasmid in PBS buffer for 2 hours. The DNA-loaded microcapsules were washed and resuspended in Optimem (cell culture medium) and then incubated with A549 (human lung carcinoma) and HeLa (human cervical epithelial carcinoma) cells at 5×105 per well for between 2 and 28 hours at 37° C. At the end of the transfection, the cells were returned to standard culture medium and harvested 28 hours from the start of the experiment. Cell lysates were prepared and luciferase activity measured using standard protocols.
- Transfection was observed, at a level approx. 1000-fold higher than for a negative control. Maximal DNA uptake was reached between 2 and 6 h, suggesting that there is no need for longer exposure times.
Claims (15)
1. A microparticle of a lipid-binding protein.
2. The microparticle according to claim 1 , comprising also a cationic or anionic molecule.
3. The microparticle according to claim 2 , comprising DC-Chol.
4. The microparticle according to claim 1 , wherein the protein is defatted albumin.
5. The microparticle according to claim 4 , wherein the albumin is human serum albumin.
6. A microparticle of a lipid-binding protein having a non-natural lipid profile.
7. The microparticle according to claim 6 , comprising also a cationic or anionic molecule.
8. The microparticle according to claim 7 , comprising DC-Chol.
9. The microparticle according to claim 6 , wherein the protein is defatted albumin.
10. The microparticle according to claim 9 , wherein the albumin is human serum albumin.
11. A method for providing enhanced ultrasound imaging, said method comprising providing the microparticles as defined in claim 6 for use as an ultrasound contrast agent.
12. A complex of a therapeutic agent and a microparticle selected from the group consisting of a microparticle of a lipid-binding protein and a microparticle of a lipid-binding protein having a non-natural lipid profile.
13. A method for treating a person or animal, said method comprising administering a therapeutic amount of a complex as defined in claim 12 .
14. A complex of DNA and a microparticle selected from the group consisting of a microparticle of a lipid-binding protein and a microparticle of a lipid-binding protein having a non-natural lipid profile.
15. A method for providing gene therapy to a person or animal, said method comprising administering a therapeutic amount of a complex as defined in claim 14.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/308,960 US20030170177A1 (en) | 1996-07-23 | 2002-12-02 | Lipid-binding proteins and their therapeutic and diagnostic use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9615435.6A GB9615435D0 (en) | 1996-07-23 | 1996-07-23 | Spray-dried product and its therapeutic use |
GB9615435.6 | 1996-07-23 | ||
US09/230,113 US6495527B1 (en) | 1996-07-23 | 1997-07-22 | Complex of DNA and microparticle of defatted lipid-binding protein for gene therapy |
US10/308,960 US20030170177A1 (en) | 1996-07-23 | 2002-12-02 | Lipid-binding proteins and their therapeutic and diagnostic use |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/230,113 Continuation US6495527B1 (en) | 1996-07-23 | 1997-07-22 | Complex of DNA and microparticle of defatted lipid-binding protein for gene therapy |
PCT/GB1997/001970 Continuation WO1998003159A2 (en) | 1996-07-23 | 1997-07-22 | Lipid-binding proteins and their therapeutic and diagnostic use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030170177A1 true US20030170177A1 (en) | 2003-09-11 |
Family
ID=10797357
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/230,113 Expired - Fee Related US6495527B1 (en) | 1996-07-23 | 1997-07-22 | Complex of DNA and microparticle of defatted lipid-binding protein for gene therapy |
US10/308,960 Abandoned US20030170177A1 (en) | 1996-07-23 | 2002-12-02 | Lipid-binding proteins and their therapeutic and diagnostic use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/230,113 Expired - Fee Related US6495527B1 (en) | 1996-07-23 | 1997-07-22 | Complex of DNA and microparticle of defatted lipid-binding protein for gene therapy |
Country Status (10)
Country | Link |
---|---|
US (2) | US6495527B1 (en) |
EP (1) | EP0918511A2 (en) |
JP (1) | JP2000514820A (en) |
AR (1) | AR008072A1 (en) |
AU (1) | AU720757B2 (en) |
CA (1) | CA2257524A1 (en) |
GB (1) | GB9615435D0 (en) |
NO (1) | NO990303L (en) |
WO (1) | WO1998003159A2 (en) |
ZA (1) | ZA976547B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011085070A2 (en) * | 2010-01-06 | 2011-07-14 | Virginia Tech Intellectual Properties, Inc. | Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058734A1 (en) * | 1999-03-26 | 2000-10-05 | Martek Biosciences Corporation | Specific binding assay for docosahexaenoic acid |
US20090280534A1 (en) * | 2004-12-22 | 2009-11-12 | Novozymes A/S | Recombinant Production of Serum Albumin |
US20080305550A1 (en) * | 2005-01-21 | 2008-12-11 | Hollie Huff | Targets for Detection of Ischemia |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4094965A (en) * | 1977-04-01 | 1978-06-13 | New England Nuclear Corporation | Diagnostic agents containing albumin and method for making same |
US4720385A (en) * | 1983-03-29 | 1988-01-19 | Miles Laboratories, Inc. | Protein compositions substantially free from infectious agents |
US4943527A (en) * | 1985-10-04 | 1990-07-24 | California Biotechnology Inc. | Mature apoai protein production under serum free culturing conditions |
US5567415A (en) * | 1993-05-12 | 1996-10-22 | The Board Of Regents Of The University Of Nebraska | Ultrasound contrast agents and methods for their manufacture and use |
US5725804A (en) * | 1991-01-15 | 1998-03-10 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US5981206A (en) * | 1992-05-20 | 1999-11-09 | Johnson & Johnson Clinical Diagnostic Systems, Inc. | Dry analytical element and method for the detection of prostatic acid phosphatase |
US6004769A (en) * | 1996-12-13 | 1999-12-21 | Merck Patent Gesellschaft | Compositions and procedures for the determination of hydrolytic enzymes |
US6352835B1 (en) * | 1998-11-17 | 2002-03-05 | Kyoto Daiichi Kagaku Co. Ltd. | Method of measuring substance in sample using a redox reaction |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
CA2199954A1 (en) | 1994-09-29 | 1996-04-04 | Andrew Derek Sutton | Spray-dried microparticles as therapeutic vehicles |
ES2191721T3 (en) * | 1994-12-16 | 2003-09-16 | Elan Drug Delivery Ltd | RETICULATED MICROPARTICLES AND ITS USE AS THERAPEUTIC VEHICLES. |
-
1996
- 1996-07-23 GB GBGB9615435.6A patent/GB9615435D0/en active Pending
-
1997
- 1997-07-22 AU AU36286/97A patent/AU720757B2/en not_active Ceased
- 1997-07-22 CA CA002257524A patent/CA2257524A1/en not_active Abandoned
- 1997-07-22 EP EP97932920A patent/EP0918511A2/en not_active Withdrawn
- 1997-07-22 JP JP10506705A patent/JP2000514820A/en active Pending
- 1997-07-22 US US09/230,113 patent/US6495527B1/en not_active Expired - Fee Related
- 1997-07-22 WO PCT/GB1997/001970 patent/WO1998003159A2/en not_active Application Discontinuation
- 1997-07-23 ZA ZA976547A patent/ZA976547B/en unknown
- 1997-07-23 AR ARP970103331A patent/AR008072A1/en unknown
-
1999
- 1999-01-22 NO NO990303A patent/NO990303L/en not_active Application Discontinuation
-
2002
- 2002-12-02 US US10/308,960 patent/US20030170177A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4094965A (en) * | 1977-04-01 | 1978-06-13 | New England Nuclear Corporation | Diagnostic agents containing albumin and method for making same |
US4720385A (en) * | 1983-03-29 | 1988-01-19 | Miles Laboratories, Inc. | Protein compositions substantially free from infectious agents |
US4943527A (en) * | 1985-10-04 | 1990-07-24 | California Biotechnology Inc. | Mature apoai protein production under serum free culturing conditions |
US5725804A (en) * | 1991-01-15 | 1998-03-10 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
US5981206A (en) * | 1992-05-20 | 1999-11-09 | Johnson & Johnson Clinical Diagnostic Systems, Inc. | Dry analytical element and method for the detection of prostatic acid phosphatase |
US5567415A (en) * | 1993-05-12 | 1996-10-22 | The Board Of Regents Of The University Of Nebraska | Ultrasound contrast agents and methods for their manufacture and use |
US6004769A (en) * | 1996-12-13 | 1999-12-21 | Merck Patent Gesellschaft | Compositions and procedures for the determination of hydrolytic enzymes |
US6352835B1 (en) * | 1998-11-17 | 2002-03-05 | Kyoto Daiichi Kagaku Co. Ltd. | Method of measuring substance in sample using a redox reaction |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011085070A2 (en) * | 2010-01-06 | 2011-07-14 | Virginia Tech Intellectual Properties, Inc. | Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts |
WO2011085070A3 (en) * | 2010-01-06 | 2011-11-24 | Virginia Tech Intellectual Properties, Inc. | Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts |
Also Published As
Publication number | Publication date |
---|---|
JP2000514820A (en) | 2000-11-07 |
AR008072A1 (en) | 1999-12-09 |
AU720757B2 (en) | 2000-06-08 |
NO990303D0 (en) | 1999-01-22 |
WO1998003159A2 (en) | 1998-01-29 |
AU3628697A (en) | 1998-02-10 |
CA2257524A1 (en) | 1998-01-29 |
EP0918511A2 (en) | 1999-06-02 |
WO1998003159A3 (en) | 1998-05-07 |
GB9615435D0 (en) | 1996-09-04 |
NO990303L (en) | 1999-03-22 |
ZA976547B (en) | 1998-07-23 |
US6495527B1 (en) | 2002-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6268053B1 (en) | Macromolecular microparticles and methods of production and use | |
EP1837018B1 (en) | Sustained release microspheres | |
EP1060741B1 (en) | Sustained release microspheres | |
US5981719A (en) | Macromolecular microparticles and methods of production and use | |
EP0495187B1 (en) | Protein nanomatrixes and method of production | |
EP0910342B1 (en) | Temperature sensitive gel for sustained delivery of protein drugs | |
US5462751A (en) | Biological and pharmaceutical agents having a nanomeric biodegradable core | |
US6613358B2 (en) | Sustained-release composition including amorphous polymer | |
US5258499A (en) | Liposome targeting using receptor specific ligands | |
US9115357B2 (en) | Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes | |
EP0826063A1 (en) | Single-vial formulations of dna/lipid complexes | |
JP2001508815A (en) | Cationic polymer / lipid nucleic acid delivery vehicle | |
US6495527B1 (en) | Complex of DNA and microparticle of defatted lipid-binding protein for gene therapy | |
EP0938299A1 (en) | Methods for the production of protein particles useful for delivery of pharmacological agents | |
EP0129619B1 (en) | Encapsulated cells, their method of preparation and use | |
Thompson et al. | Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing-hormone | |
CZ20031559A3 (en) | Microparticles with improved release profile and method for the production thereof | |
Kohane et al. | pH-triggered release of macromolecules from spray-dried polymethacrylate microparticles | |
CN101237855A (en) | Lipid construct for delivery of interferon to a mammal | |
JPH08505403A (en) | Stable proteins: phospholipid compositions and methods | |
US5419914A (en) | Phospholipid analogue vesicle | |
Mishra et al. | Reverse biomembrane vesicles for effective controlled delivery of doxorubicin HCl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ELAN DRUG DELIVERY LTD., UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:QUADRANT HEALTHCARE LIMITED;REEL/FRAME:013692/0524 Effective date: 20020919 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |